A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy

Eur J Cancer. 2020 Apr:129:1-3. doi: 10.1016/j.ejca.2020.01.009. Epub 2020 Feb 21.

Authors

Alice Indini¹, Maria Sessa², Barbara Merelli¹, Camillo Foresti², Mario Mandalà³

Affiliations

¹ Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
² Unit of Neurology, Department of Neuroscience, Papa Giovanni XXIII Hospital, Bergamo, Italy.
³ Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address: mmandala@asst-pg23.it.

PMID: 32092585
DOI: 10.1016/j.ejca.2020.01.009

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects
Antirheumatic Agents / therapeutic use
Diagnosis, Differential
Eye Enucleation
Guillain-Barre Syndrome / chemically induced
Guillain-Barre Syndrome / diagnosis
Guillain-Barre Syndrome / drug therapy*
Guillain-Barre Syndrome / immunology
Humans
Infliximab / therapeutic use*
Liver Neoplasms / drug therapy*
Liver Neoplasms / secondary
Male
Melanoma / therapy*
Nivolumab / adverse effects*
Radiosurgery
Radiotherapy, Adjuvant
Treatment Outcome
Uveal Neoplasms / therapy*

Substances

Antineoplastic Agents, Immunological
Antirheumatic Agents
Nivolumab
Infliximab

Supplementary concepts

Uveal melanoma